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Six hybridoma clones producing monoclonal antibodies (MAbs) reactive with Pasteurella haemolytica Al
leukotoxin were derived from mice immunized with leukotoxin excised from sodium dodecyl sulfate-
polyacrylamide gels. Of the six MAbs, only one, Ltx-2, neutralized leukotoxin in a BL-3 cell cytotoxicity assay.
MAb Ltx-2 blocked association of Al leukotoxin to BL-3 cells, as measured by flow cytometric analysis. The
epitope recognized by Ltx-2 was localized to the carboxyl half of the native protein, between residues 450 and
939, by Western immunoblot analysis of CNBr fragments. Further analysis with leukotoxin deletion proteins
indicated either that the Ltx-2-reactive epitope was localized in the carboxyl portion of the leukotoxin between
amino acids 768 and 939 or that this region influences MAb recognition of the epitope. MAb Ltx-2 was tested
for neutralizing activity against leukotoxin produced by P. haemolytica serotypes 1 through 12. The MAb
neutralized leukotoxin produced by all of the A biotype isolates (serotypes 1, 5, 6, 7, 8, 9, and 12), with the
exception of serotype A2, but did not neutralize any T biotype leukotoxin tested (T3, T4, or T10). The results
indicate that MAb Ltx-2 neutralizes leukotoxin by interfering with target cell association and that the
MAb-specific epitope is either not present or not critical for function in the leukotoxin produced by P.
haemolytica serotypes A2, T3, T4, and T10.
The ruminant-specific leukotoxin produced by Pasteurella
haemolytica Al is generally considered an important viru-
lence determinant in the pathogenesis of bovine pneumonic
pasteurellosis (1). Acting as a Ca2"-dependent pore-former
(6, 14), the toxin is believed to promote bacterial prolifera-
tion by killing or incapacitating phagocytes (12, 19). More-
over, leukotoxin-damaged phagocytes may contribute to the
severe localized inflammatory response characteristic of this
disease (34). Natural field resistance is associated with
circulating titers of neutralizing antibodies (13), and such
antibodies are detectable in lung fluids of calves protectively
immunized by aerosol exposure to viable P. haemolytica Al
(29). In addition, recombinant leukotoxin has been used with
measurable success as an experimental vaccine component
(7).
The leukotoxin has been cloned and sequenced (20, 25, 26)
and has significant homology with a variety of potential
pore-forming toxins collectively characterized as the RTX
toxin family (24, 35). Toxins in the RTX family have tan-
demly repeating glycine-rich sequences believed, at least for
the Escherichia coli alpha-hemolysin, to serve as a function-
ally critical Ca2+-binding region (3, 27). In addition, P.
haemolytica leukotoxin shares with alpha-hemolysin an ex-
tended hydrophobic region containing a predicted mem-
brane-spanning domain which is necessary to effect cytolysis
(24, 30). The carboxy-terminal amino acids, at least for the
alpha-hemolysin, appear to function in secretion (11), while
the amino-terminal region appears to facilitate cytolysis,
perhaps in the initial stages of host membrane insertion (37).
Binding and cytolysis appear to be separable events (9, 27),
and recent evidence indicates that lysis-defective mutant
leukotoxin proteins with whole or partial deletions of the
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membrane-spanning region retain the capacity to bind to
target cells and to competitively inhibit cytolysis by native
leukotoxin (8).
Monoclonal antibodies (MAbs) prepared against the al-
pha-hemolysin have helped to further define important do-
mains within the toxin (22, 30), including a potentially
important domain between the membrane-spanning region
and the repeating glycine-rich domain that contains an
epitope which, when bound by antibody, results in potent
neutralization (31, 37). Similar investigations have not been
performed with MAbs directed against P. haemolytica Al
leukotoxin.
We report here the production of murine MAbs raised
against P. haemolytica Al leukotoxin. One leukotoxin-
neutralizing MAb which blocked association of the leuko-
toxin with sensitive target cells was identified. Further
evaluation revealed that the epitope recognized by the
neutralizing MAb was distributed or expressed differently in
leukotoxins produced by different P. haemolytica serotypes
and most notably was either absent or not critical for the
toxic effects of leukotoxins from T biotypes and A2 sero-
types. Preliminary epitope mapping indicated that the neu-
tralizing antibody binds to a site located between residues
450 and 939 of the intact 953-residue native leukotoxin.
MATERIALS AND METHODS
Bacteria. The Al P. haemolytica strain used to generate
leukotoxin for the production of antibodies was isolate
88-1165, provided by R. D. Walker, Michigan State Univer-
sity, East Lansing, Mich. Additional P. haemolytica sero-
types were obtained either from G. Frank, National Animal
Disease Center, Ames, Iowa, or the American Type Culture
Collection, Rockville, Md. These organisms were main-
tained on blood agar consisting of BHI agar (BBL, Cockeys-
ville, Md.) and 5% defibrinated sheep blood, grown at 37°C
1734











NEUTRALIZING MAb TO P. HAEMOLYTICA LEUKOTOXIN 1735
(36). The organisms were stored in sterile skim milk at
-700C.
Cell culture. The BL-3 bovine leukemia-derived B-lym-
phocyte cell line used for the cytotoxicity assays was pro-
vided by G. H. Theilen, University of California, Davis.
BL-3 cells were grown in RPMI 1640 medium (Sigma Chem-
ical Company, St. Louis, Mo.) supplemented with 10% fetal
bovine serum (Hyclone Laboratories, Logan, Utah), L-glu-
tamine, and penicillin-streptomycin (Sigma) at 37°C in a
humidified atmosphere of 5% CO2 in air.
Leukotoxin production. Leukotoxin filtrates were prepared
from log-phase P. haemolytica as described by Shewen and
Wilkie (33). The supernatant culture medium was passed
through a 0.2-,um-pore-size filter (Corning Glass Works,
Coming, N.Y.) and concentrated 100-fold with a Pellicon
concentrator equipped with a 30-kDa exclusion membrane
(Millipore, Bedford, Mass.). The concentrated filtrate was
aliquoted and stored at -70°C.
Cytotoxicity assay. Leukotoxin was measured by the neu-
tral red cytotoxicity assay with BL-3 target cells, as reported
by Greer and Shewen (16). Percent cytotoxicity was deter-
mined as the ratio of A540 in test wells with leukotoxin to
A540 in control wells (16, 25). One unit of leukotoxin is
defined as the dilution of filtrate sample determined to yield
50% cytotoxicity (14). The leukotoxin-neutralizing capacity
of the various antibodies was determined with the same
assay except that a preselected dilution of leukotoxin was
incubated with antibody dilutions for 1 h at 40C prior to
addition to the BL-3 cells.
MAb production. Eight-week-old female BALB/c mice
(Harlan Sprague-Dawley, Indianapolis, Ind.) were immu-
nized with the 102-kDa leukotoxin band (26) excised from
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) gels. Briefly, 2 mg of protein from the concen-
trated culture filtrate was stacked at a constant 100 mA,
followed by electrophoresis at a constant 120 mA through
the separating gel for approximately 5 h. SDS-PAGE was
performed as described by Laemmli (23) with a Protean Gel
apparatus (Bio-Rad Laboratories, Richmond, Calif.). Stack-
ing and separating gels consisting of 5 and 7% acrylamide
(acrylamide-bisacrylamide, 30:0.8), respectively, were used
to separate the leukotoxin-containing filtrate. Following
electrophoresis, the 102-kDa protein was visualized by light
Coomassie blue staining (18), excised, lyophilized, mascer-
ated, and suspended in 12 ml of 0.1 M sodium phosphate-
buffered physiological saline (pH 7.2; PBS). Mice were
immunized by intraperitoneal injection of 0.4 ml of the
suspension and boosted at 4 weeks with an identical injec-
tion. Mice with detectable antileukotoxin titers in the en-
zyme-linked immunosorbent assay (ELISA) were given a
third injection after 2 weeks, and 72 h later, splenocytes
were fused with Sp2/0-Agl4 cells (American Type Culture
Collection) as described by Fazekas de St. Groth and
Scheidegger (10). Hybridomas selected by positive ELISA
screening with crude concentrated filtrate were cloned by
limiting dilution, and antibody isotypes were determined
with the immunoselective Isotyping System (Bio-Rad). As-
cites were generated for each positive clone (18), and the
immunoglobulin G (IgG) was purified from the ascites by
using immobilized protein G (Gamma Bind Plus Pre Pack;
Genex Corporation, Gaithersburg, Md.). All protein concen-
trations were determined with a Bradford method kit (Bio-
Rad). Rabbit antiserum specific for leukotoxin was prepared
by subcutaneous injection of New Zealand White rabbits
with the electrophoretically purified leukotoxin described
above at monthly intervals.
ELISA. Both direct and capture ELISAs were used. For
the direct assay, concentrated crude filtrate, diluted to 1 jig
of protein per well in carbonate buffer (0.01 M, pH 9.6), was
affixed to the wells of 96-well Immulon II plates (Dynatech,
Chantilly, Va.) overnight at 4°C. Unreactive sites were
blocked with 3% bovine serum albumin (Sigma) in PBS
(PBS-BSA). Culture media and purified ascites IgG were
diluted in PBS containing 0.05% Tween-20 (Sigma; PBS-
Tween) and incubated in the ELISA wells for 1 h at 37°C.
The wells were washed three times with PBS-Tween and
then incubated with protein G-horseradish peroxidase (HRP)
(Genex) at 37°C for 1 h. The wells were washed with
PBS-Tween, and bound antibody-protein G-HRP was de-
tected with ABTS [2,2'-azino-di-(3-ethyl-benzthiazoline-6-
sulfonic acid)] and H202 (Sigma) in an automated Microplate
reader (Bio-Tek, Burlington, Vt.).
Western immunoblot. SDS-PAGE of samples was per-
formed in a Mini Protean II Gel Apparatus (Bio-Rad) with
precast 4 to 15% gradient gels (Bio-Rad). Concentrated
leukotoxin filtrate protein (2 jig per lane) was electro-
phoresed for 90 min with constant amperage of 14 mA and
transferred to Immobilon-P polyvinylidene difluoride (PVDF)
membranes (Millipore) with a semidry protein apparatus
(Gelman, Ann Arbor, Mich.) in 0.025 M Tris buffer (pH 8.2)
containing 0.19 M glycine and 0.1 M SDS. The membranes
were washed in Tris-buffered saline (TBS), immersed in 3%
gelatin (Bio-Rad) in TBS, and incubated at 37°C for 1 h to
block residual protein-binding sites. The membranes were
washed in deionized H20 and then in TBS with 0.05%
Tween-20 (TBS-Tween) and incubated with antibody over-
night at room temperature. Bound antibody was detected,
following deionized H20 and TBS-Tween washes, with
protein G-HRP (Genex) followed by 4-chloro-1-naphthol and
30% H202 (Sigma). Development was terminated by wash-
ing the membranes with several changes of deionized H20.
Transferred protein was stained on PVDF membranes by the
India ink method of Hancock and Tsang (17).
Flow cytometry. Binding of cells by antibodies was per-
formed as described by Harlow and Lane (18). Briefly,
concentrated Al and A2 culture filtrates were preincubated
for 50 min at 4°C with 20 jig of MAb Ltx-2 in a total volume
of 100 jil containing 100 U of leukotoxin. BL-3 cells (106 in
35 ,ul of PBS) were then added, and the suspension was
incubated for an additional 30 min at 37°C. Following three
cycles of low-speed centrifugation and washing with cold
PBS containing 3% BSA and 0.02% sodium azide, the cells
were treated with rabbit antileukotoxin antibody for 1 h at
4°C and washed three times as described above. To detect
cell-bound rabbit antileukotoxin antibodies, the cells were
treated with fluorescein-conjugated donkey anti-rabbit im-
munoglobulin antibody (Jackson Laboratories, West Grove,
Pa.). After a wash, single-color fluorescence analysis was
performed with a FACScan fluorescence-activated cell
sorter (Becton Dickinson, San Jose, Calif.).
Plasmid manipulations. Plasmids containing internal dele-
tions of the lktA gene were derived from pYFC19 (4, 8), in
which the lktCA genes are expressed under lacPO control.
The methods for generating the deletion alleles carried by
pDS14 (codons 34 to 378), pWC25 (codons 246 to 357),
pDS25 (codons 358 to 548), and pDS27 (codons 549 to 768)
have been described previously (8). The carboxyl-terminal
truncation carried by pWC64 was generated by introducing a
universal translational terminator (Pharmacia) into the ClaI
site of pYFC19. The leukotoxin deletion protein expressed
from pWC64 is missing the carboxyl-terminal 185 residues of
























FIG. 1. Immunoblot of MAbs reacting with SDS-PAGE of con-
centrated Al leukotoxin filtrate transferred to PVDF membrane.
Total proteins are visualized in the India ink lane, and the 2° only
lane is a control without primary antibody.
prepared by growing Escherichia coli TBl harboring the
various plasmids in BHI broth to an OD550 of >2.0. Six-
milliliter late-logarithmic-phase cultures were washed and
precipitated with 10% trichloroacetic acid (TCA) (8). The
total cellular protein was washed once with methanol to
remove TCA and boiled in 0.5 ml of SDS-PAGE sample
buffer, and 25 ,ul of sample was processed for Western
blotting.
CNBr cleavage of leukotoxin. CNBr cleavage was per-
formed as described by Changchien et al. (5) and Oropeza-
Wekerle et al. (30). Briefly, 150 mg of CNBr (Sigma) was
dissolved in 1.5 ml of 70% formic acid. Then, 0.5 ml of this
mixture was added to 18 ,ug of lyophilized leukotoxic filtrate
protein and incubated at room temperature for 48 h. An
equal amount of deionized H20 was added to this mixture,
which was then lyophilized. The lyophilized product was
rehydrated with a minimal volume of deionized H20 and
subjected to SDS-PAGE.
RESULTS
MAb characterization. Six hybridoma clones producing
MAbs reactive by ELISA with concentrated leukotoxin-
containing filtrate were derived from mice immunized with
electrophoretically purified leukotoxin. All six MAbs re-
acted with a protein band at approximately 102 kDa upon
Western immunoblot following SDS-PAGE of the crude
concentrated leukotoxin (Fig. 1); however, only Ltx-2, an
IgGl MAb, displayed neutralizing activity for the leuko-
toxin. With sensitive BL-3 target cells, Ltx-2 effected 50%
neutralization of 3 and 1 U of leukotoxin activity at 300 and
30 ng/ml, respectively (Fig. 2).
Epitope distribution among serotype leukotoxins. Leuko-
toxin production is a characteristic of all P. haemolytica
serotypes (21, 32). Therefore, MAb Ltx-2 was tested for
neutralization of the leukotoxin produced by other P. hae-
molytica serotypes. Culture filtrates from isolates represent-
ing serotypes 1 through 12 were adjusted to 1 and 4 U and
incubated with Ltx-2 at 25 ,ug/ml, a concentration of the
antibody at least 100-fold greater than required to neutralize
3 U of Al toxin (Fig. 2). The results are given in Table 1.
MAb Ltx-2 neutralized leukotoxic activity derived from
serotypes 1, 5, 6, 7, 8, 9, and 12 at both 4 and 1 U. However,
the MAb did not neutralize the leukotoxic activity produced
by serotypes 2, 3, 4, and 10. All of the leukotoxins neutral-
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FIG. 2. MAb Ltx-2 neutralization of Al leukotoxin. Serial dilu-
tions of MAb were preincubated with either 3 or 1 U of leukotoxin,
and inhibition of cytotoxicity for BL-3 cells was determined by the
neutral red cytotoxicity assay.
5, 6, 7, 8, 9, and 12). A2 leukotoxin was the only A biotype
toxin that was not neutralized by MAb Ltx-2. The remaining
leukotoxins that were not neutralized were produced by
serotypes classified in biotype T (T3, T4, and T10). The
serotype 11 strain tested did not produce leukotoxin and is
not shown in the table.
Further testing of MAb Ltx-2 revealed that the MAb did
not react by ELISA with A2 P. haemolytica leukotoxin and
reacted too faintly in the Western immunoblot for photo-
graphic reproduction. In addition, when Ltx-2 reactivity
with T3, T4, and T10 leukotoxins was assessed by Western
immunoblot, reactivity was detected only with the T10
leukotoxin band (not shown).
Effect of MAb Ltx-2 on leukotoxin-target cell interaction.
MAb Ltx-2 could effect toxin neutralization either by influ-
encing a critical function or site involved in pore formation
or by preventing association of the toxin with the target cell.
Flow cytometry was performed to determine whether Ltx-2
acted to block the association of Al leukotoxin with the
BL-3 cells. Leukotoxin was incubated with and without
Ltx-2 and then added to the target cells. Leukotoxin asso-
ciated with the target cells was detected by adding rabbit
antisera raised against electrophoretically purified leuko-
toxin followed by fluorescein isothiocyanate-labeled anti-
TABLE 1. Neutralization of leukotoxin activity from log-phase
culture filtrates of P. haemolytica serotypesa
P. haemolytica % Cytotoxicity? (mean + SE, n = 3)
serotype 1U 1U+Ab 4U 4U+Ab
1 43 3 0 1 97 1 12 3
2 65 8 67 1 96 1 97±0
2 69 3 71 4 90 4 92 3
3 30 3 34 5 85 3 76f+4
4 60 3 70±4 98 1 99 1
5 55 2 3 5 1000 0± 2
6 40 7 0 4 99 1 0 4
7 63 2 0 3 1000 0± 3
8 60 6 0 3 100 3 0 3
9 50 5 0 3 100 3 0 1
10 42 5 48±7 87 1 86 1
10 (ATCC) 45 5 60 5 92 1 85+2
12 50 8 0 5 95 5 0 3
a All strains were from the collection of G. Frank unless denoted ATCC
(American Type Culture Collection).
b Percent cytotoxicity for BL-3 cells was determined by uptake of neutral
red. The amount (units) of leukotoxin or leukotoxin preincubated with MAb
Ltx-2 at 25 pLg/ml (Ab) is indicated. Underlined values represent cytotoxicity

























FIG. 3. Flow cytometry detecting Al or A2 leukotoxin associated with BL-3 target cells. Leukotoxin was incubated with MAb-Ltx-2 prior
to addition to BL-3 cells. Following addition to BL-3 cells, cell-bound leukotoxin was detected by using rabbit antileukotoxin followed by
FITC-labeled donkey anti-rabbit immunoglobulin antisera. Solid lines ( ) represent leukotoxins without MAb Ltx-2 preincubation. Dotted
lines (.... ) represent leukotoxins preincubated with the MAb. (A) Binding of Al leukotoxin; (B) binding of A2 leukotoxin.
rabbit immunoglobulin antisera. Preincubation of leukotoxin
with MAb Ltx-2 blocked its association with the target cells
(Fig. 3A). Fifty percent of the BL-3 cells were positive for
bound leukotoxin. Preincubation of the toxin with Ltx-2
reduced this percentage to essentially 0, which was not
different from the FITC-labeled control. As an additional
control, the same experiment was performed with A2 leuko-
toxin. The detecting rabbit anti-Al leukotoxin antiserum
effectively neutralized A2 leukotoxin in addition to Al (not
shown). MAb Ltx-2 did not prevent the association of A2
leukotoxin with BL-3 cells (Fig. 3B). Without Ltx-2, 52% of
the BL-3 cells were positive for bound A2 leukotoxin.
Preincubation of the toxin with Ltx-2 did not reduce this
value; approximately 60% of the cells were positive for
bound A2 leukotoxin. Thus, Al leukotoxin, which is neu-
tralized by the MAb, was prevented from associating with
the target cells, while the MAb did not prevent the binding of
or neutralize the A2 leukotoxin.
Preliminary epitope mapping. CNBr cleavage fragments
and mutant deletion proteins of the leukotoxin were used to
provide preliminary generalized localization of the epitope
recognized by MAb Ltx-2. The native leukotoxin contains
five methionine residues at amino acid positions 1, 156, 408,
449, and 939 (26). Following complete CNBr cleavage, only
one band was detected by immunoblot after SDS-PAGE.
This band migrated at about 50 kDa, approximately the mass
of an expected 490-amino-acid cleavage fragment containing
amino acids 450 to 939 (Fig. 4).
The derivatives of pYFC19 with deletions of the lktA4 gene
are presented in Fig. 5. These mutated genes in the E. coli
host, TBl, produced truncated proteins with deletions
across virtually the entire protein. MAb Ltx-2 immunoblots
of SDS-PAGE gels of 10% TCA-precipitated intact cells
revealed single bands for all the truncated proteins except
pWC64, which had a deletion of the carboxy terminus
beginning at amino acid 768. Although not shown in the
immunoblot (Fig. 4), this truncated protein was visualized by
both rabbit and bovine antileukotoxin antisera (8) and was
detectable by India ink stain. The weakly stained band for
pDS25 was also weakly visualized by rabbit and bovine
antileukotoxin antisera, indicating lesser production of this
mutant protein.
Results with the deletion proteins confirmed the CNBr
localization of Ltx-2 reactivity within the carboxyl half of the
native protein and suggested possible localization of an
epitope between amino acids 768 and 939. However, this
indirect approach was not definitive, and the possibility of





FIG. 4. Immunoblots of CNBr cleavage fragments and Al leu-
kotoxin deletion proteins. Lyophilized culture filtrate was cleaved
with CNBr dissolved in 70% formic acid, and SDS-PAGE and
immunoblotting with MAb-Ltx-2 were performed following lyoph-
ilization and resuspension in distilled H20. The deletion protein
samples were TCA precipitates of E. coli TB1 harboring the various






FIG. 5. Deletion maps of mutant lktA genes derived from
pYFC19. Deleted segments are represented by checkered blocks.
Restriction enzyme sites in pYFC19 are: A, NaeI; P, PvuII; N, NsiI;
M, MluI; and C, ClaI. The solid boxes in pYFC19 represent
potential membrane-spanning regions, and the glycine-aspartic acid
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recognition by Ltx-2 is influenced by the 768 to 939 se-
quence, cannot be excluded.
DISCUSSION
Shewen and Wilkie (32) prepared specific antisera against
serotypes 1 through 12 of P. haemolytica and reported
various degrees of leukotoxin cross-neutralization. Type-
specific rabbit serum neutralized homologous toxin and, to a
degree, heterologous toxin. These implied antigenic differ-
ences between serotype toxins are further supported by the
present study. MAb Ltx-2 neutralized leukotoxin from most,
but not all, of the 12 serotypes tested. The MAb neutralized
all but one of the A biotype leukotoxins but failed to
neutralize leukotoxin from any of the three T biotypes.
Furthermore, by Western immunoblot, Ltx-2 reacted only
with one of the three T biotype toxins, T10. Although the
present findings can be regarded only as preliminary, the
results obtained with this MAb indicate that the epitope is
either missing in T biotype leukotoxin or is not critical for
leukotoxic activity. While definitive proof will require test-
ing of additional T biotype isolates and eventual cloning and
sequencing of T biotype lktA, the results suggest that se-
quence and/or conformational differences exist between the
leukotoxins from A and T biotypes in addition to differential
fermentation of arabinose and trehalose, the current discrim-
inator between the two biotypes (2).
It is additionally interesting that the epitope for MAb
Ltx-2 was not definitively demonstrable in A2 leukotoxin.
Al and A2 isolates predominate as causes of pneumonia in
domestic ruminants. Al is the most frequent agent associ-
ated with bovine disease, while A2 is the most frequent
isolate from sheep (12, 15). Again, definite proof will require
testing of additional A2 isolates and eventual cloning and
sequencing of A2 1ktA; however, this observation is sugges-
tive of sequence or conformational differences between Al
and A2 leukotoxin as well as between A and T leukotoxin.
This potential difference is further strengthened by the
failure of additional Al-derived MAbs to react with A2
leukotoxin. By ELISA, only one of the nonneutralizing
MAbs, Ltx-81, clearly reacted with the A2 leukotoxin.
Although the majority of nonneutralizing MAbs reacted with
denatured A2 leukotoxin by Western blot analysis, MAb
Ltx-35 failed to react even under these conditions. Thus, at
least two Al epitopes could not be definitively detected in
A2 leukotoxin.
The nature of the epitope recognized by MAb Ltx-2 is
unclear. The MAb reacted weakly with toxin that had been
affixed to ELISA wells in alkaline carbonate buffer. Ltx-2,
however, was a very potent neutralizer of soluble toxin, and
although the titration is not presented in the Results section,
Ltx-2 reacted very well by ELISA when the leukotoxin was
trapped by other toxin-specific MAbs. Apparently, the
epitope recognized by the MAb is more accessible when the
leukotoxin is in soluble form rather than affixed directly to
the ELISA well. Recognition of the epitope by immunoblot
following the denaturing conditions of SDS-PAGE suggests
that the epitope is continuous rather than discontinuous.
The mechanism by which the leukotoxin associates with
target cell membranes has not been elucidated. The Ca2+-
binding glycine-rich repeat domain is critical for RTX toxin
effects and has been proposed to function in binding (24, 27).
However, it remains unclear whether this requirement is
important in initial recognition or at a secondary stage.
Regardless, binding and pore formation appear to be sepa-
rable events (9, 27), and evidence reported by Cruz et al. (8)
indicates that the binding functions are distinct from the lytic
functions of Al leukotoxin. Mutant toxins with whole or
partial deletions of the putative membrane-spanning regions
agglutinated BL-3 cells and, in addition, were antagonistic
for cell lysis by native leukotoxin. In the present study, MAb
Ltx-2 prevented the leukotoxin from associating with the
target cells, as measured by flow cytometry, suggesting that
the MAb neutralizes the toxin by preventing its initial
association with the target cell membrane. Thus, the MAb
may react with an epitope associated with the binding
domain of the leukotoxin. Conversely, Ltx-2 binding may
prevent association of the leukotoxin by interfering with
transitional-state changes or even by enhancing leukotoxin
inactivation. The correct interpretation obviously will re-
quire further investigation; however, it is interesting that
preliminary mapping positions the epitope in an amino acid
sequence devoid of potential membrane-spanning regions
but containing at least the last two repeats in the glycine-rich
repeat domain. Work is in progress to localize this poten-
tially important epitope more precisely.
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